查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1947824

預防醫學基因檢測市場分析及預測（至2035年）：依類型、產品類型、服務、技術、組件、應用、最終使用者、流程、模式及階段分類

Genetic Testing for Preventive Health Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Component, Application, End User, Process, Mode, Stage
出版日期: | 出版商: Global Insight Services | 英文 313 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

預計到2034年，預防性醫療保健基因檢測市場規模將從2024年的100億美元成長至382億美元，複合年成長率約為15%。該市場涵蓋用於識別疾病遺傳易感性的檢測，從而實現主動健康管理。這些檢測可以指南個人化的生活方式調整和醫療干預，有助於疾病的早期發現和預防。意識提升和基因組學技術的進步正在推動市場成長，凸顯了精準醫療和個人化醫療保健解決方案的重要性。

在人們對個人化醫療和預防保健意識不斷增強的推動下，預防性醫療保健基因檢測市場持續穩定成長。其中，預測性檢測領域成長最為迅猛，該領域評估疾病的遺傳易感性，並支持預防性醫療決策。癌症易感性檢測尤其受到關注，這主要歸因於遺傳性癌症發生率的上升。成長速度第二快的領域是藥物基因組學領域，該領域能夠深入了解個別藥物反應，並有助於最佳化治療策略。直接面對消費者的基因檢測正在蓬勃發展，反映出消費者在健康管理方面擁有更多自主權。基因組學和生物資訊學領域的技術進步提高了檢測的準確性和可及性，進一步推動了市場成長。人工智慧在基因分析中的應用簡化了數據解讀，並提升了預測能力。倫理考量和資料隱私仍然至關重要，它們塑造著法規結構並影響市場動態。各相關人員的合作正在推動創新，並擴大預防性醫療保健解決方案的範圍。

市場區隔
種類 預測性檢測、基因帶原檢測、產前檢測、新生兒篩檢、藥物基因組學檢測、營養基因組學檢測
產品 檢測套組、試劑、耗材、軟體
服務 遺傳諮詢、檢查室檢測、數據解讀和諮詢服務
科技 次世代定序、聚合酵素鏈鎖反應、微陣列、SNP基因型鑒定、CRISPR
成分 硬體、軟體和服務
應用領域 腫瘤科、心臟科、神經科、感染疾病、內分泌科
最終用戶 醫院、診所、檢查室、實驗室和居家醫療環境
過程 檢體採集、DNA提取、定序、數據分析和報告生成
實施例 院內實施、外包
步 研究與開發、臨床試驗和商業化

預防性醫療保健基因檢測市場的特徵是市場佔有率、定價策略和產品創新之間存在著動態的相互作用。主要企業正利用其市場地位，推出尖端基因檢測產品，以滿足日益增強的健康意識的消費者的需求。為了將基因檢測推廣到更廣泛的受眾，定價策略的競爭日益激烈。新產品的頻繁發布反映了基因研究和技術的快速發展。這些發展創造了一個充滿活力的市場環境，並蘊藏著成長和多元化的潛力。基因檢測市場的競爭異常激烈，主要參與者致力於獲得技術優勢和市場佔有率。監管具有顯著影響，基因檢測的核准和商業化都受到嚴格的標準約束。北美和歐洲等地區擁有領先的法規結構，確保了基因檢測的高品質標準。各公司透過與行業領導者進行對標來改進產品並保持合規性。市場格局凸顯了個人化醫療的發展趨勢，基因檢測在預防性醫療保健策略中發揮關鍵作用。基因組學研究的進步和意識提升推動了這一發展趨勢。

主要趨勢和促進因素：

在人們對遺傳疾病和個人化醫療的認知不斷提高的推動下，預防性醫療保健基因檢測市場持續穩定成長。一個關鍵趨勢是將人工智慧 (AI) 應用於基因檢測，這提高了檢測的準確性並降低了成本。這項技術進步使基因檢測更易於獲取，並吸引了更多人。此外，直接面對消費者 (DTC) 的基因檢測服務的普及，使個人能夠做出明智的健康決策。另一個關鍵促進因素是慢性病發病率上升，促使人們轉向預防性醫療保健。隨著全球醫療保健系統優先考慮早期診斷和干涉，基因檢測正成為必不可少的工具。此外，基因組學的進步和定序技術成本的下降也推動了市場成長。這些發展使得更全面、更經濟的檢測選擇成為可能。新興市場醫療保健基礎設施的快速發展蘊藏著許多機會。能夠提供擴充性且經濟高效的解決方案的公司將佔據有利地位，贏得市場佔有率。此外，生物技術公司與醫療保健提供者之間的合作正在推動創新，並擴大基因檢測服務的覆蓋範圍。隨著支持基因檢測的法規結構不斷發展，市場有望持續成長和創新。

目錄

第1章執行摘要

第2章 市場亮點

第3章 市場動態

  • 宏觀經濟分析
  • 市場趨勢
  • 市場促進因素
  • 市場機遇
  • 市場限制
  • 複合年均成長率：成長分析
  • 影響分析
  • 新興市場
  • 技術藍圖
  • 戰略框架

第4章 細分市場分析

  • 市場規模及預測：依類型
    • 預測性測試
    • 基因帶原檢測
    • 產前檢查
    • 新生兒篩檢
    • 藥物基因組學檢測
    • 營養基因體學檢測
  • 市場規模及預測：依產品分類
    • 檢測套組
    • 試劑
    • 消耗品
    • 軟體
  • 市場規模及預測：依服務分類
    • 遺傳諮詢
    • 檢查室檢測
    • 數據解讀
    • 諮詢服務
  • 市場規模及預測：依技術分類
    • 次世代定序
    • 聚合酵素鏈鎖反應
    • 微陣列
    • SNP基因分型
    • CRISPR
  • 市場規模及預測：依組件分類
    • 硬體
    • 軟體
    • 服務
  • 市場規模及預測：依應用領域分類
    • 腫瘤學
    • 心臟病學
    • 神經病學
    • 感染疾病
    • 內分泌學
  • 市場規模及預測：依最終用戶分類
    • 醫院
    • 診所
    • 診斷實驗室
    • 研究所
    • 居家醫療環境
  • 市場規模及預測：依製程分類
    • 檢體採集
    • DNA萃取
    • 定序
    • 數據分析
    • 報告
  • 市場規模及預測：依實施方法分類
    • 內部
    • 外包
  • 市場規模及預測：依階段分類
    • 研究與開發
    • 臨床試驗
    • 商業化

第5章 區域分析

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地區
  • 亞太地區
    • 中國
    • 印度
    • 韓國
    • 日本
    • 澳洲
    • 台灣
    • 亞太其他地區
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 西班牙
    • 義大利
    • 其他歐洲地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 撒哈拉以南非洲
    • 其他中東和非洲地區

第6章 市場策略

  • 需求與供給差距分析
  • 貿易和物流限制
  • 價格、成本和利潤率趨勢
  • 市場滲透率
  • 消費者分析
  • 法規概述

第7章 競爭訊息

  • 市場定位
  • 市場占有率
  • 競爭基準
  • 主要企業的策略

第8章 公司簡介

  • 23and Me
  • Color Genomics
  • Veritas Genetics
  • Invitae
  • Myriad Genetics
  • Counsyl
  • Blueprint Genetics
  • Genomic Health
  • Ambry Genetics
  • Fulgent Genetics
  • Centogene
  • Pathway Genomics
  • Gene by Gene
  • Natera
  • Sema4
  • Progenity
  • Personalis
  • Helix
  • Orchid Health
  • Prevention Genetics

第9章：關於我們

簡介目錄
Product Code: GIS32828

Genetic Testing for Preventive Health Market is anticipated to expand from $10.0 billion in 2024 to $38.2 billion by 2034, growing at a CAGR of approximately 15%. The Genetic Testing for Preventive Health Market encompasses tests identifying genetic predispositions to diseases, enabling proactive health management. These tests guide personalized lifestyle adjustments and medical interventions, fostering early disease detection and prevention. Rising consumer awareness and advancements in genomics propel market growth, emphasizing the importance of precision medicine and tailored healthcare solutions.

The Genetic Testing for Preventive Health Market is experiencing robust expansion, propelled by increasing awareness of personalized medicine and preventive care. The predictive testing segment is the top performer, driven by its ability to assess genetic predispositions to diseases, enabling proactive healthcare decisions. Within this segment, cancer susceptibility testing is particularly prominent, given the rising incidence of hereditary cancers. Pharmacogenomics follows as the second highest performing segment, offering insights into individual drug responses and optimizing therapeutic strategies. Direct-to-consumer genetic testing is gaining momentum, reflecting a shift towards consumer empowerment in health management. Technological advancements in genomics and bioinformatics are enhancing test accuracy and accessibility, further boosting market growth. The integration of artificial intelligence in genetic analysis is streamlining data interpretation, improving predictive capabilities. Ethical considerations and data privacy remain critical, shaping regulatory frameworks and influencing market dynamics. Collaborative efforts among stakeholders are fostering innovation and expanding the scope of preventive health solutions.

Market Segmentation
TypePredictive Testing, Carrier Testing, Prenatal Testing, Newborn Screening, Pharmacogenomic Testing, Nutrigenomic Testing
ProductTest Kits, Reagents, Consumables, Software
ServicesGenetic Counseling, Laboratory Testing, Data Interpretation, Consultation Services
TechnologyNext-Generation Sequencing, Polymerase Chain Reaction, Microarray, SNP Genotyping, CRISPR
ComponentHardware, Software, Services
ApplicationOncology, Cardiology, Neurology, Infectious Diseases, Endocrinology
End UserHospitals, Clinics, Diagnostic Laboratories, Research Institutes, Home Care Settings
ProcessSample Collection, DNA Extraction, Sequencing, Data Analysis, Report Generation
ModeIn-house, Outsourced
StageResearch and Development, Clinical Trials, Commercialization

The genetic testing for preventive health market is characterized by a dynamic interplay of market share, pricing strategies, and product innovation. Leading companies are leveraging their market position to introduce cutting-edge genetic tests, targeting an increasingly health-conscious consumer base. Pricing strategies are becoming more competitive, as companies aim to make genetic testing more accessible to a broader audience. New product launches are frequent, reflecting the rapid advancements in genetic research and technology. These developments are fostering a vibrant market environment, with significant potential for growth and diversification. Competition in the genetic testing market is intense, with key players striving for technological superiority and market share. Regulatory influences are significant, as stringent standards govern the approval and commercialization of genetic tests. Regions like North America and Europe are leading in regulatory frameworks, ensuring high-quality standards in genetic testing. Companies are benchmarking against industry leaders to enhance their offerings and maintain compliance. The market's analytical landscape reveals a trend toward personalized medicine, with genetic testing playing a crucial role in preventive health strategies. This evolution is supported by advancements in genomic research and increasing consumer awareness.

Geographical Overview:

The genetic testing for preventive health market is witnessing substantial growth across diverse regions, each with unique opportunities. North America leads the market, driven by advanced healthcare infrastructure and increased consumer awareness about preventive health measures. The region's strong emphasis on personalized medicine further accelerates market expansion. Europe follows closely, with robust government initiatives and funding aimed at integrating genetic testing into public health strategies. The Asia Pacific region is experiencing rapid growth, propelled by rising healthcare expenditures and a growing middle class keen on preventive health. Emerging economies like China and India are pivotal in this expansion, offering lucrative opportunities for market players. Latin America is gradually gaining traction, with countries such as Brazil investing in healthcare innovation. Meanwhile, the Middle East & Africa are emerging as potential growth pockets, with increasing healthcare investments and a growing focus on preventive health measures contributing to market development.

The Genetic Testing for Preventive Health Market is dynamically influenced by global tariffs, geopolitical risks, and evolving supply chain trends. In Japan and South Korea, government-backed initiatives are bolstering domestic biotech capabilities to mitigate reliance on foreign genetic testing technologies amid trade tensions. China is accelerating its genomic research and development to counteract export restrictions, fostering a robust local ecosystem. Taiwan, while a pivotal player in biotech manufacturing, navigates geopolitical sensitivities with strategic partnerships. Globally, the market is witnessing robust growth driven by increased health awareness and technological advancements. By 2035, the market is poised for significant expansion, contingent upon resilient supply chains and international collaborations. Middle East conflicts could indirectly influence energy prices, affecting operational costs and supply chain stability across the sector.

Key Trends and Drivers:

The Genetic Testing for Preventive Health Market is experiencing robust expansion due to heightened awareness of genetic disorders and personalized medicine. A major trend is the integration of artificial intelligence in genetic testing, enhancing accuracy and reducing costs. This technological advancement is making genetic testing more accessible and appealing to a broader audience. Furthermore, direct-to-consumer genetic testing services are gaining popularity, empowering individuals to make informed health decisions. Another significant driver is the increasing prevalence of chronic diseases, prompting a shift towards preventive healthcare. As healthcare systems worldwide prioritize early diagnosis and intervention, genetic testing is becoming an essential tool. Additionally, advancements in genomics and the decreasing cost of sequencing technologies are propelling market growth. These developments are enabling more comprehensive and affordable testing options. Opportunities abound in emerging markets where healthcare infrastructure is rapidly improving. Companies that can offer scalable and cost-effective solutions are well-positioned to capture market share. Moreover, collaborations between biotechnology firms and healthcare providers are fostering innovation and expanding the reach of genetic testing services. As regulatory frameworks evolve to support genetic testing, the market is poised for sustained growth and innovation.

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Component
  • 2.6 Key Market Highlights by Application
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Process
  • 2.9 Key Market Highlights by Mode
  • 2.10 Key Market Highlights by Stage

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Predictive Testing
    • 4.1.2 Carrier Testing
    • 4.1.3 Prenatal Testing
    • 4.1.4 Newborn Screening
    • 4.1.5 Pharmacogenomic Testing
    • 4.1.6 Nutrigenomic Testing
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Test Kits
    • 4.2.2 Reagents
    • 4.2.3 Consumables
    • 4.2.4 Software
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Genetic Counseling
    • 4.3.2 Laboratory Testing
    • 4.3.3 Data Interpretation
    • 4.3.4 Consultation Services
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 Next-Generation Sequencing
    • 4.4.2 Polymerase Chain Reaction
    • 4.4.3 Microarray
    • 4.4.4 SNP Genotyping
    • 4.4.5 CRISPR
  • 4.5 Market Size & Forecast by Component (2020-2035)
    • 4.5.1 Hardware
    • 4.5.2 Software
    • 4.5.3 Services
  • 4.6 Market Size & Forecast by Application (2020-2035)
    • 4.6.1 Oncology
    • 4.6.2 Cardiology
    • 4.6.3 Neurology
    • 4.6.4 Infectious Diseases
    • 4.6.5 Endocrinology
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Hospitals
    • 4.7.2 Clinics
    • 4.7.3 Diagnostic Laboratories
    • 4.7.4 Research Institutes
    • 4.7.5 Home Care Settings
  • 4.8 Market Size & Forecast by Process (2020-2035)
    • 4.8.1 Sample Collection
    • 4.8.2 DNA Extraction
    • 4.8.3 Sequencing
    • 4.8.4 Data Analysis
    • 4.8.5 Report Generation
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 In-house
    • 4.9.2 Outsourced
  • 4.10 Market Size & Forecast by Stage (2020-2035)
    • 4.10.1 Research and Development
    • 4.10.2 Clinical Trials
    • 4.10.3 Commercialization

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Component
      • 5.2.1.6 Application
      • 5.2.1.7 End User
      • 5.2.1.8 Process
      • 5.2.1.9 Mode
      • 5.2.1.10 Stage
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Component
      • 5.2.2.6 Application
      • 5.2.2.7 End User
      • 5.2.2.8 Process
      • 5.2.2.9 Mode
      • 5.2.2.10 Stage
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Component
      • 5.2.3.6 Application
      • 5.2.3.7 End User
      • 5.2.3.8 Process
      • 5.2.3.9 Mode
      • 5.2.3.10 Stage
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Component
      • 5.3.1.6 Application
      • 5.3.1.7 End User
      • 5.3.1.8 Process
      • 5.3.1.9 Mode
      • 5.3.1.10 Stage
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Component
      • 5.3.2.6 Application
      • 5.3.2.7 End User
      • 5.3.2.8 Process
      • 5.3.2.9 Mode
      • 5.3.2.10 Stage
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Component
      • 5.3.3.6 Application
      • 5.3.3.7 End User
      • 5.3.3.8 Process
      • 5.3.3.9 Mode
      • 5.3.3.10 Stage
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Component
      • 5.4.1.6 Application
      • 5.4.1.7 End User
      • 5.4.1.8 Process
      • 5.4.1.9 Mode
      • 5.4.1.10 Stage
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Component
      • 5.4.2.6 Application
      • 5.4.2.7 End User
      • 5.4.2.8 Process
      • 5.4.2.9 Mode
      • 5.4.2.10 Stage
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Component
      • 5.4.3.6 Application
      • 5.4.3.7 End User
      • 5.4.3.8 Process
      • 5.4.3.9 Mode
      • 5.4.3.10 Stage
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Component
      • 5.4.4.6 Application
      • 5.4.4.7 End User
      • 5.4.4.8 Process
      • 5.4.4.9 Mode
      • 5.4.4.10 Stage
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Component
      • 5.4.5.6 Application
      • 5.4.5.7 End User
      • 5.4.5.8 Process
      • 5.4.5.9 Mode
      • 5.4.5.10 Stage
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Component
      • 5.4.6.6 Application
      • 5.4.6.7 End User
      • 5.4.6.8 Process
      • 5.4.6.9 Mode
      • 5.4.6.10 Stage
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Component
      • 5.4.7.6 Application
      • 5.4.7.7 End User
      • 5.4.7.8 Process
      • 5.4.7.9 Mode
      • 5.4.7.10 Stage
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Component
      • 5.5.1.6 Application
      • 5.5.1.7 End User
      • 5.5.1.8 Process
      • 5.5.1.9 Mode
      • 5.5.1.10 Stage
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Component
      • 5.5.2.6 Application
      • 5.5.2.7 End User
      • 5.5.2.8 Process
      • 5.5.2.9 Mode
      • 5.5.2.10 Stage
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Component
      • 5.5.3.6 Application
      • 5.5.3.7 End User
      • 5.5.3.8 Process
      • 5.5.3.9 Mode
      • 5.5.3.10 Stage
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Component
      • 5.5.4.6 Application
      • 5.5.4.7 End User
      • 5.5.4.8 Process
      • 5.5.4.9 Mode
      • 5.5.4.10 Stage
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Component
      • 5.5.5.6 Application
      • 5.5.5.7 End User
      • 5.5.5.8 Process
      • 5.5.5.9 Mode
      • 5.5.5.10 Stage
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Component
      • 5.5.6.6 Application
      • 5.5.6.7 End User
      • 5.5.6.8 Process
      • 5.5.6.9 Mode
      • 5.5.6.10 Stage
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Component
      • 5.6.1.6 Application
      • 5.6.1.7 End User
      • 5.6.1.8 Process
      • 5.6.1.9 Mode
      • 5.6.1.10 Stage
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Component
      • 5.6.2.6 Application
      • 5.6.2.7 End User
      • 5.6.2.8 Process
      • 5.6.2.9 Mode
      • 5.6.2.10 Stage
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Component
      • 5.6.3.6 Application
      • 5.6.3.7 End User
      • 5.6.3.8 Process
      • 5.6.3.9 Mode
      • 5.6.3.10 Stage
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Component
      • 5.6.4.6 Application
      • 5.6.4.7 End User
      • 5.6.4.8 Process
      • 5.6.4.9 Mode
      • 5.6.4.10 Stage
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Component
      • 5.6.5.6 Application
      • 5.6.5.7 End User
      • 5.6.5.8 Process
      • 5.6.5.9 Mode
      • 5.6.5.10 Stage

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 23and Me
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Color Genomics
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Veritas Genetics
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Invitae
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 Myriad Genetics
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Counsyl
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Blueprint Genetics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Genomic Health
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Ambry Genetics
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Fulgent Genetics
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 Centogene
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 Pathway Genomics
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Gene by Gene
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Natera
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Sema4
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Progenity
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Personalis
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 Helix
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 Orchid Health
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Prevention Genetics
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us